Testosterone Replacement in United States 2026
Testosterone has moved from a niche urology topic to front-page news in the summer of 2026. Defense Secretary Pete Hegseth announced in mid-July that the US military will begin annual testosterone deficiency screening for all service members ages 30 and older, framing the initiative as a way to “optimize” troop health and combat readiness. The announcement landed in the middle of an already-booming national conversation around testosterone replacement therapy (TRT), which has shifted over the past several years from a treatment reserved for men with clinically confirmed hormone deficiency into what many outlets now describe as a mainstream cultural phenomenon built around performance, longevity, and men’s health.
The scale of that shift shows up clearly in the prescribing data: US testosterone prescriptions climbed from roughly 7.3 million in 2019 to over 11 million in 2024, a jump of about 50% in five years. At the same time, medical experts have raised real concerns about both the new military policy and the broader boom, noting that up to a third of men currently taking testosterone were never formally diagnosed with a deficiency in the first place. This article draws together the latest verified 2026 data on TRT usage, the new military testing mandate, national hypogonadism prevalence, and the safety evidence behind one of the fastest-growing treatment categories in American men’s health.
Testosterone Replacement Facts US 2026
| Fact | Figure |
|---|---|
| US testosterone prescriptions, 2019 | ~7.3 million |
| US testosterone prescriptions, 2024 | 11+ million |
| Increase in prescriptions, 2019-2024 | ~50% |
| Men taking testosterone without formal deficiency diagnosis | Up to 1/3 (American Urological Association) |
| American men over 45 with hypogonadism | ~40% |
| Men in their 80s with hypogonadism | ~50% |
| Hypogonadal men who actually receive TRT | Only 5%-35% |
| Military service members newly subject to annual T screening | Ages 30 and older |
| Out-of-pocket cost for non-covered TRT refill (TRICARE) | Up to $85 |
| Testosterone decline per year after age 30 | ~1% |
Source: CBS News 2025 prescription data; SingleCare Low Testosterone Facts and Statistics 2026; American Urological Association guidance; Federal News Network, July 2026
The jump from 7.3 million to over 11 million annual US testosterone prescriptions between 2019 and 2024 captures a genuinely fast-moving shift in American men’s healthcare, and it’s a trend that predates the current military testing controversy by several years. What makes the scale of this growth more complicated from a clinical standpoint is the finding that up to a third of men currently on testosterone were never formally diagnosed with deficiency, according to American Urological Association guidance, meaning a meaningful share of current users may not be treating a confirmed medical condition in the way the therapy was originally designed for.
On the prevalence side, hypogonadism itself is genuinely common and climbs steeply with age: roughly 40% of American men over 45 and nearly 50% of men in their 80s meet criteria for low testosterone, yet only an estimated 5% to 35% of those men actually receive treatment, reflecting long-documented underdiagnosis in primary care. Testosterone also declines gradually as a normal part of aging, dropping roughly 1% per year after age 30, which is the baseline physiological pattern the new military screening program for service members 30 and older is now designed to formally track across the armed forces.
Military Testosterone Screening Statistics 2026
| Metric | Detail |
|---|---|
| Announcement date | Mid-July 2026 |
| Announced by | Defense Secretary Pete Hegseth |
| Mandatory screening age group | 30 and older |
| Voluntary screening age group | Under 30 (opt-in) |
| Treatment decision | Voluntary, left to patient |
| TRICARE coverage | Covers TRT for diagnosed hypogonadism |
| Out-of-pocket cost, brand-name/non-covered drugs | Up to $85 per refill |
| Deployment impact | Waiver typically required before deploying overseas |
Source: Healthline, “U.S. Military’s Testosterone Mandate Raises Concern Among Experts,” July 20, 2026; Federal News Network, July 2026
The core structure of the new policy is straightforward: service members aged 30 and older will be screened for testosterone deficiency as part of their annual health assessments, while those under 30 can request testing voluntarily. Importantly, being screened does not mean being treated — if a doctor recommends TRT based on the results, the decision to actually begin therapy is left entirely to the individual service member. TRICARE, the military’s health program, already covers standard hormone replacement formulations like injections, gels, and patches for troops diagnosed with male hypogonadism or similar conditions, though service members choosing a brand-name drug or a medication outside the covered formulary could still pay up to $85 per refill out of pocket.
The policy carries practical downstream consequences beyond the blood test itself. Troops who begin TRT typically need a medical waiver before deploying overseas, since not all testosterone medications are approved for use in deployed settings, meaning a positive diagnosis and subsequent treatment could directly affect a service member’s deployment eligibility. This detail is part of why the policy has drawn scrutiny from medical experts, who note that a single blood test cannot reliably diagnose low testosterone on its own — accurate diagnosis requires additional confirmed symptoms alongside a second confirmatory blood test taken at a specific time of day, a nuance that has fueled debate over whether a blanket annual screening program is the most clinically sound approach, separate from the question of whether it’s a reasonable use of military health resources. This debate over screening broad populations for hormone or metabolic conditions echoes similar discussions playing out in the wider men’s health field, covered in more depth in the Men’s Health Statistics in the U.S report.
Hypogonadism Prevalence Statistics US 2026
| Age/Population Group | Hypogonadism Prevalence |
|---|---|
| American men over 45 | ~40% |
| Men in their 80s | ~50% |
| Men over 65 with low free testosterone (below age 30-35 norms) | 60%+ |
| Adult males overall (general range) | 10%-40% |
| Adolescent and young adult men (15-39 years) | ~20% |
| Total US men affected by hypogonadism | 4-5 million (clinically estimated) |
| Men with Type 2 diabetes or obesity who have hypogonadism | 30%-50% |
Source: National Institutes of Health, 2024; Boston University Medical Center, “Prevalence, Diagnosis and Treatment of Hypogonadism in Primary Care Practice”; Endocrine Society, 2022
National estimates place hypogonadism at somewhere between 4 and 5 million American men, though the condition’s true prevalence varies enormously depending on the population studied and the diagnostic threshold used. Clinical studies find more than 60% of men over 65 have free testosterone levels below the normal range for men aged 30 to 35, while broader population estimates put overall adult male prevalence somewhere in a wide 10% to 40% range. What stands out in the more recent data is that low testosterone isn’t purely an older man’s condition: research using National Health and Nutrition Examination Survey data found testosterone deficiency prevalence of roughly 20% among adolescent and young adult men aged 15 to 39, with serum testosterone levels in this age group actually declining over time when compared across NHANES survey cycles from 1999 through 2016, even after controlling for rising body mass index.
The connection between hypogonadism and metabolic health is one of the strongest patterns in the epidemiological data: 30% to 50% of men with Type 2 diabetes or obesity also have hypogonadism, according to Endocrine Society guidance, a relationship researchers describe as bidirectional, since low testosterone can worsen metabolic function just as metabolic disease can suppress testosterone production. This overlap is a significant part of why hypogonadism prevalence estimates vary so widely between studies — a population sample skewed toward men with diabetes or obesity will show meaningfully higher rates than a general population sample, and it also connects to broader patterns in male reproductive health explored in the Sperm Count Decline Statistics in US report, where declining testosterone and declining sperm parameters are frequently discussed as related, if not identical, trends.
TRT Prescribing Trends by Age Group US 2026
| Age Group | 2013 Prescribing Rate | 2025-2026 Prescribing Rate |
|---|---|---|
| All men (overall trend) | 0.83% (2013 peak) | 0.95% (partial 2026) |
| Ages 18-29 | Lowest of all groups | 0.14% |
| Ages 50-64 | N/A | 1.57% (highest of all groups) |
| Ages 24 and under (growth, 2018-2022) | Baseline | More than doubled |
| Ages 25-34 (growth, 2018-2022) | Baseline | 86% increase |
| Injectable formulation market share | N/A | ~55% |
Source: Epic Research, “After Nearly a Decade-Long Decrease, Testosterone Prescribing Rates Rising Again,” using Cosmos dataset covering 310+ million patient records
National prescribing data reveals a genuine U-shaped pattern over the past decade: the share of male patients with an active testosterone prescription fell from a 2013 peak of 0.83% down to a low of 0.64% by 2021, before reversing sharply and climbing to 0.93% in 2025 and 0.95% in the first half of 2026. This recent resurgence has been broad-based rather than concentrated in any single age group, with every age category 30 and older surpassing its early-2010s peak by 2025, and men aged 50 to 64 showing the highest overall prescribing prevalence at 1.57%.
What’s genuinely new about this cycle, compared with the previous decade’s TRT boom, is where the fastest growth is actually happening: between 2018 and 2022, testosterone therapy prevalence more than doubled among men 24 and under, and rose 86% among men aged 25 to 34, even though these younger groups still have the lowest absolute prescribing rates of any age bracket at just 0.14% for the youngest cohort. This pattern shows the growth is being driven disproportionately by younger men rather than by the older, traditionally hypogonadal population the therapy was originally developed for, a dynamic widely attributed to expanding direct-to-consumer telehealth clinics and shifting cultural attitudes toward hormone optimization as a wellness category rather than strictly a medical treatment.
TRT Safety and Clinical Evidence Statistics US 2026
| Metric | Finding |
|---|---|
| TRAVERSE trial size | 5,000+ men |
| Cardiovascular event risk (TRT vs. placebo) | No increased risk of heart attack or stroke |
| Elevated risk identified in TRAVERSE | Atrial fibrillation, pulmonary embolism, acute kidney injury |
| FDA cardiovascular black-box warning status | Removed in February 2025 |
| Fertility impact | Reduces testicle size and sperm count |
| Guideline caution for men planning children | AUA and Endocrine Society both advise against TRT use |
| TRT market size projection by 2032 | $2.9 billion (4.2% CAGR) |
Source: TRAVERSE trial, New England Journal of Medicine, 2023; FDA testosterone labeling update, February 2025; American Urological Association and Endocrine Society guidelines
The most important piece of safety evidence underpinning the entire 2026 testosterone conversation is the TRAVERSE trial, a landmark study of more than 5,000 men that found testosterone replacement therapy did not increase the risk of heart attack or stroke compared with placebo — a genuinely reassuring finding after years of conflicting research on cardiovascular safety, and one significant enough that the FDA removed its longstanding cardiovascular black-box warning from testosterone products in February 2025. That said, the same trial identified higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury among men taking testosterone, meaning the therapy isn’t risk-free even though its most feared cardiovascular risks were not confirmed.
Fertility remains one of the clearest and most consistent risks associated with testosterone therapy: TRT reduces testicle size and suppresses sperm production, which is why both the American Urological Association and the Endocrine Society explicitly caution against testosterone use in men who plan to have children. This fertility risk is particularly relevant given the demographic shift toward younger users described earlier in this report, since men in their 20s and early 30s are statistically more likely to still be planning families than the traditionally older hypogonadal patient population TRT was originally developed to treat, a dynamic that connects directly to broader national trends covered in the Infertility Statistics in the U.S report, where male-factor infertility is examined as a contributor alongside female-factor causes. With the broader testosterone replacement therapy market projected to reach $2.9 billion by 2032, growing at a 4.2% compound annual rate, the commercial incentive behind continued TRT expansion shows no sign of slowing even as the clinical conversation around who genuinely needs treatment, and who is taking on unnecessary fertility risk in the process, remains very much unresolved.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
